()
 
 

Overview

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales.


Contact Information

6030 - 88th Street
Edmonton, AB T6E6G4

tel: 780-413-7152
fax:
http://www.biomsmedical.com

,  



Investor Relations


Ryan Giese
tel:
fax:
e-mail: info@biomsmedical.com




Stock

Exchange: TSX
Industry: Industrial
Market Cap: $216.5M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.